| Literature DB >> 26589361 |
Susan M Huse1, Philip A Gruppuso2,3, Kim Boekelheide1, Jennifer A Sanders4,5.
Abstract
BACKGROUND: DNA methylation is an important epigenetic control mechanism that has been shown to be associated with gene silencing through the course of development, maturation and aging. However, only limited data are available regarding the relationship between methylation and gene expression in human development.Entities:
Mesh:
Year: 2015 PMID: 26589361 PMCID: PMC4654795 DOI: 10.1186/s12864-015-2066-3
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Fig. 1Analysis of gene expression in fetal and adult liver. Microarray data were analyzed by GSEA (a) and IPA (b). Blue bars and red bars reflect higher expression in the fetal and adult samples, respectively. Results are stratified based on level of significance. GSEA data are shown as the FDR q-value. IPA results show the unadjusted p-value. The threshold for significance of the IPA results was determined using fetal (blue arrow) and adult (red arrow) control data sets, as described in Methods
Fig. 2Distribution of methylation data. Methylation sites were stratified based on the average methylation level. a A histogram showing the number of CpGs at any given methylation level was generated using intervals of 0.05 for the range of 0 to 1. All methylation sites were included in the determination of the mean of triplicate samples for each site. Fetal results are shown in blue and adult in red. b The difference in methylation between fetal and adult data sets, calculated as the average delta beta for each site, is shown as a histogram. For this analysis, sites were included only if there was a q-significant difference between fetal and adult
Fig. 3Distribution of DNA methylation based on gene region. Triplicate fetal (blue) and adult (red) samples were analyzed using all CpGs that were found to be methylated. The solid lines represent sites within 1,500 base pairs of the transcription start site or within the first exon, and the dashed lines those sites that are within the gene body, 5’UTR or 3’UTR
Fig. 4The relationship between DNA methylation and gene expression. Results are shown as the average methylation for each gene (mean beta value for the sites on that gene) versus the mean fetal:adult expression ratio for each gene. Data for the three fetal samples (blue) and the three adult samples (red) were filtered using various parameters to generate the input for the analysis. a All genes for which methylation was significantly different for fetal versus adult (q < 0.05). b Genes for which the fetal:adult difference in methylation (dβ) was at least 0.2. c Significant methylation; methylation restricted to TSS/Ex1 CpGs. d Significant methylation; methylation restricted to TSS/Ex1 CpGs for which dβ was at least 0.2
Fig. 5Methylation of genes overexpressed in fetal liver. Overexpression was defined as a q-significant 5-fold difference in mean expression level between fetal and adult. a Fetal (blue) and adult (red) TSS/Ex1 methylation (FDR q < 0.05 with dβ >0.2) results are shown juxtaposed against one another. Also shown are methylation results for fetal (b) and adult (c) liver relative to data generated using randomly selected gene sets for which fetal and adult liver expression was similar (fetal:adult ratio of −1.1 to +1.1; gray bars)
Figure 6Methylation of genes overexpressed in adult liver. Overexpression was defined as a q-significant 5-fold difference in mean expression level between fetal and adult. a Fetal (blue) and adult (red) TSS/Ex1 methylation (FDR q < 0.05 with dβ >0.2) results shown juxtaposed against one another. Also shown are methylation results for fetal (b) and adult (c) liver relative to data generated using randomly selected gene sets for which fetal and adult liver expression was similar (fetal:adult ratio of −1.1 to +1.1; gray bars)
I PA categories, genes and p-values for Cannonical Pathways
| Pathway | Genes | P-value |
|---|---|---|
| Nicotine Degradation II | FMO3,CYP1A1,UGT2B7,CYP2C18,CYP2C9,INMT,CYP1B1,UGT2B15, CYP1A2,CYP2D6,CYP2E1,CYP2A6,CYP2B6,AOX1,CYP2C8 | 5.62 × 10−18 |
| Nicotine Degradation III | CYP1A1,UGT2B7,CYP2C18,CYP2C9,CYP1B1,UGT2B15,CYP1A2,CYP2E1, CYP2D6,CYP2A6,AOX1,CYP2B6,CYP2C8 | 1.54 × 10−15 |
| Bupropion Degradation | CYP1A1,CYP1A2,CYP2E1,CYP2D6,CYP2C18,CYP2C9,CYP2A6,CYP2B6, CYP1B1,CYP2C8 | 5.92 × 10−14 |
| Acetone Degradation I (to Methylglyoxal) | CYP1A1,CYP1A2,CYP2E1,CYP2D6,CYP2C18,CYP2C9,CYP2A6,CYP2B6, CYP1B1,CYP2C8 | 5.92 × 10−14 |
| Melatonin Degradation I | CYP1A1,CYP1A2,UGT2B7,CYP2E1,CYP2D6,CYP2C18,CYP2C9,CYP2A6, CYP2B6,CYP1B1,CYP2C8,UGT2B15 | 6.05 × 10−14 |
| Estrogen Biosynthesis | CYP1A1,CYP1A2,CYP2E1,CYP2D6,CYP2C18,CYP2C9,CYP2A6,CYP2B6, AKR1C4,CYP1B1,CYP2C8 | 8.47 × 10−14 |
| Superpathway of Melatonin Degradation | CYP1A1,CYP1A2,UGT2B7,CYP2E1,CYP2D6,CYP2C18,CYP2C9,CYP2A6, CYP2B6,CYP1B1,CYP2C8,UGT2B15 | 1.61 × 10−13 |
| PXR/RXR Activation | CYP1A2,CES3,CYP2C9,CYP2A6,CYP2B6,SULT2A1,CYP2C8 | 7.87 × 10−6 |
| LPS/IL-1 Mediated Inhibition of RXR Function | FMO3,SLC27A5,SLC10A1,ACSL4,CYP2C9,CYP2A6,CYP2B6,ABCC4, SULT2A1,CYP2C8 | 3.92 × 10−5 |
Percentage of CpG sites by location category and methylation level
| Gene Expression | Tissue | Location on Gene | Number of CpGs | Hypomethylation (%) | Intermediate Methylation (%) | Hypermethylation (%) |
|---|---|---|---|---|---|---|
| Fetal Overexpressed | Fetal | TSS/Ex1 | 1640 | 76 | 10 | 14 |
| UTR/GB | 2312 | 31 | 11 | 58 | ||
| Adult | TSS/Ex1 | 1640 | 71 | 11 | 18 | |
| UTR/GB | 2312 | 27 | 15 | 58 | ||
| Adult Overexpressed | Fetal | TSS/Ex1 | 912 | 47 | 16 | 37 |
| UTR/GB | 957 | 24 | 16 | 61 | ||
| Adult | TSS/Ex1 | 912 | 56 | 24 | 20 | |
| UTR/GB | 957 | 24 | 21 | 55 | ||
| Similarly Expressed | Fetal | TSS/Ex1 | 2464 | 43 | 34 | 23 |
| UTR/GB | 4983 | 31 | 37 | 32 | ||
| Adult | TSS/Ex1 | 2464 | 16 | 60 | 23 | |
| UTR/GB | 4983 | 12 | 57 | 30 |
CpGs were selected based on their relationship to genes whose expression differed significantly between fetal and adult liver (q < 0.05; fold-difference >5), or their relationship to genes that were similarly expressed in the two groups (fold-difference ≤1.1). Based on criteria described in the text, CpGs were then categorized as localized to within 200 or 1,500 base pairs of the transcription start site or the first exon (TSS/Ex1), or within the 5’UTR, 3’UTR or gene body, and as showing hypo-, intermediate or hypermethylation
Prediction Probability of DNA Methylation Change to Gene Expression Change
| Gene expression induced in adult | ||||
| Fetal Hypermethylation | Location | Number of CpGs | >2-Fold | >5-Fold |
| Fetal-to-Adult Decrease >0.2 | TSS/Ex1 | 3,510 | 20 % | 7 % |
| UTR/GB | 8,807 | 12 % | 2 % | |
| Fetal-to-Adult Decrease >0.5 | TSS/Ex1 | 391 | 33 % | 11 % |
| UTR/GB | 1,350 | 14 % | 2 % | |
| Gene Expression Induced in Fetus | ||||
| Adult Hypermethylation | Location | Number of CpGs | >2-Fold | >5-Fold |
| Fetal-to-Adult Increase >0.2 | TSS/Ex1 | 22,587 | 7 % | 2 % |
| UTR/GB | 54,769 | 5 % | 2 % | |
| Fetal-to-Adult Increase >0.5 | TSS/Ex1 | 25,706 | 7 % | 2 % |
| UTR/GB | 62,226 | 5 % | 2 % | |
CpGs were categorized based on fetal-to-adult differences in methylation status and their location within genes (TSS/Ex1 versus UTR/GB). Their predictive value was assigned based on the fetal:adult difference in expression of the genes to which the respective CpGs were assigned
Fig. 7Distribution of gene region-specific methylation for genes overexpressed in fetal or adult liver. For all graphs, the density of fetal methylation is shown in blue and adult in red. Solid lines represent the density plots for genes that are 5-fold overexpressed in fetal liver (left) or adult liver (right). Results for genes that were equally expressed in fetal and adult liver (fetal:adult ratio of −1.1 to +1.1) are shown for comparison purposes as dotted lines. Methylation data were filtered based on a significant (q < 0.05) difference of at least 0.2. The graphs are grouped in rows based on gene regions: CpGs within 200 base pairs of the transcription start site (TSS200), within 1,500 base pairs of the transcription start site (TSS1500), or within the 5’UTR, 1st exon, gene body, or 3’UTR